Citizens Lifts Price Target for Taysha Gene Therapies (TSHA)

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the 12 Best American Penny Stocks to Buy Right Now. On November 5, Citizens increased its price target on Taysha Gene Therapies, Inc. (NASDAQ:TSHA) from $6 to $8 and kept a Market Outperform rating.

Citizens noted the finalization of the company’s REVEAL pivotal trial for Rett syndrome treatment. The research firm said that the protocol is “the best approach in Rett,” giving Taysha Gene Therapies, Inc. (NASDAQ:TSHA) a huge competitive advantage.

According to Citizens’ analysis, the company has finalized its pivotal protocol and statistical analysis plan. Taysha Gene Therapies, Inc. (NASDAQ:TSHA) now plans to start the trial in Q4 2025. The company has followed new draft guidelines from the FDA.

Citizens noted that continuity in communication with the FDA despite changes in agency leadership should help reduce regulatory risks for Taysha Gene Therapies, Inc.’s (NASDAQ:TSHA) development program. The research firm raised its probability of success estimate for the company’s Rett Syndrome program from 33% to 55%.

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is a clinical-stage biotechnology company. It focuses on developing adeno-associated virus (AAV)-based gene therapies to treat serious monogenic diseases of the central nervous system.

While we acknowledge the potential of TSHA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Stocks Under $20 to Buy According to Analysts and 12 Best Performing Stocks in the Last 3 Months.

Disclosure: None. This article is originally published at Insider Monkey.